常山药业 (300255)
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 91906.09
- Circulating A-Shares(W): 91769.59
- Earnings Per Share(RMB): -0.0500
- Net Assets Per Share(RMB): 1.6508
- Operating Revenue(W RMB): 68122.15
- Total Profit(W RMB): -5434.02
- Net Profit Attributable to Parent(W RMB): -4481.74
- Net Profit Growth Rate(%): -714.77
- Weighted Return on Equity(%): -2.9100
- Operating Cash Flow Per Share(RMB): 0.1550
- Undistributed Profit Per Share(RMB): -0.0108
- Capital Reserve Per Share(RMB): 0.4600
2. Main Business
The main business covers:
- Research, development, production and sales of drugs for the treatment of cardiovascular and cerebrovascular diseases.
3. Company Basic Information
- Company Name: Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
- Listing Date: 2011-08-19
- Industry: Pharmaceutical Manufacturing
- Address: No. 71, Menglong Street, South District, High-tech Industrial Development Zone, Zhengding County, Zhengding Area, China (Hebei) Pilot Free Trade Zone.
- Website: www.hbcsbio.com
- Company Profile: The Company was established on November 20, 2009, as a joint stock company converted from Changshan Co., Ltd. based on its audited net assets as of September 30, 2009, pursuant to a resolution passed at the shareholders' meeting of Changshan Co., Ltd. on October 26, 2009. According to the Audit Report issued by Zhongxi Certified Public Accountants on October 26, 2009, the audited net asset value of Changshan Co., Ltd. as of the audit base date of September 30, 2009 was RMB 112,353,171.03. According to the Asset Appraisal Report issued by Beijing Jingdu Zhongxin Asset Appraisal Co., Ltd. on October 29, 2009, the appraised value of the net assets of Changshan Co., Ltd. as of the appraisal base date of September 30, 2009 was RMB 164.1218 million. The Company converted the audited net asset value into share capital of RMB 73.5 million, and the remaining RMB 38,853,171.03 was recorded as the capital reserve of the joint stock company. On November 5, 2009, Zhongxi Certified Public Accountants issued the Capital Verification Report, confirming that the promoters' capital contributions had been fully paid. The Hebei Provincial Administration for Industry and Commerce issued the Business License on November 20, 2009, with the registration number 130000000011859 and registered capital of RMB 73.5 million.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hebei Huaxu Chemical Co., Ltd. | General Legal Person | 2085.95 | 2.27 |
| 2 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 389.44 | 0.42 |
| 3 | Qingdao Xinde Huachang Investment Management Co., Ltd. | General Legal Person | 244.00 | 0.27 |
| 4 | E Fund ChiNext Mid Cap 200 ETF | Fund | 24.56 | 0.03 |
| 5 | Guoshou Anbao SZSE ChiNext Mid Cap Select 88 ETF | Fund | 10.32 | 0.01 |
| 6 | ChinaAMC ChiNext Mid Cap 200 ETF | Fund | 5.73 | 0.01 |
| 7 | Guotai ChiNext Pharmaceuticals and Health Care ETF | Fund | 4.51 | 0.00 |
| 8 | China Southern ChiNext Mid Cap 200 ETF | Fund | 1.93 | 0.00 |
| 9 | Fullgoal ChiNext Mid Cap 200 ETF | Fund | 1.45 | 0.00 |
| 10 | Yinhua ChiNext Mid Cap 200 ETF | Fund | 0.28 | 0.00 |
5. Concept Sectors
- Xiong'an New Area
- Generic Drugs
- Medical Aesthetics Concept
- Innovative Drugs
- Weight Loss Drugs
- Margin Trading & Securities Lending
- High Price-to-Book Ratio
- Consecutive Losses
- Equity Transfer
- Newly Added Constituent
- Non-Cyclical Stocks
- ChiNext Index
- SZSE 300 Index
- ChiNext 50 Index
- ChiNext 300 Index
- ChiNext Growth Index
- ChiNext Large Cap Index
- ChiNext Pharmaceuticals Index
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information